Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Illumina sues Oxford Nanopore

    Hi all,

    Illumina sues Oxford Nanopore...

    http://www.genomeweb.com/sequencing-...t-infringement

    Curious to have your opinion about this....

  • #2
    Looks like ONT has become a threat.
    Illumina used to scoff at them.

    Competition is good for customers. Illumina is a one-trick pony and their technology is headed to the glue factory.

    Comment


    • #3
      Patent fights converge to the more wealthy team as winner.

      Comment


      • #4
        The patents in question as reported by BioIT World
        Discover the latest news in bioinformatics, biomedical research, and drug discovery. Bio-IT World provides topical news coverage and analysis of cutting-edge biotechnologies to deliver individualized medicine.


        Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

        Mycobacterium smegmatis nanopores and related methods

        Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

        MSP nanopores and related methods

        Comment


        • #5
          Originally posted by SylvainL View Post
          Illumina sues Oxford Nanopore...
          Booo...

          Hopefully the fact that they are not a US company will shield them somewhat.

          Comment


          • #6
            Originally posted by narain View Post
            Patent fights converge to the more wealthy team as winner.
            That's blatantly not true, take the recent IBS V Illumina case as an example.

            Ever heard of David V Goliath?

            Comment


            • #7
              While it is likely that this is Illumina's tactic to stall or distract ONT, WashU being one of plaintiffs does give this claim a little bit of credibility.

              Comment


              • #8
                Originally posted by Brian Bushnell View Post
                Booo...

                Hopefully the fact that they are not a US company will shield them somewhat.
                I thought discrimination was not tolerated on this site!?

                Comment

                Latest Articles

                Collapse

                • seqadmin
                  Essential Discoveries and Tools in Epitranscriptomics
                  by seqadmin


                  The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist on Modified Bases...
                  Yesterday, 07:01 AM
                • seqadmin
                  Current Approaches to Protein Sequencing
                  by seqadmin


                  Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
                  04-04-2024, 04:25 PM

                ad_right_rmr

                Collapse

                News

                Collapse

                Topics Statistics Last Post
                Started by seqadmin, 04-11-2024, 12:08 PM
                0 responses
                39 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 04-10-2024, 10:19 PM
                0 responses
                41 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 04-10-2024, 09:21 AM
                0 responses
                35 views
                0 likes
                Last Post seqadmin  
                Started by seqadmin, 04-04-2024, 09:00 AM
                0 responses
                55 views
                0 likes
                Last Post seqadmin  
                Working...
                X